Business Description
Zai Lab Ltd
ISIN : US98887Q1040
Share Class Description:
ZLAB: ADR Repr 1 ShsTotal Employee Number:
1,797Compare
Compare
Traded in other countries / regions
ZLAB.USA09688.Hong Kong1ZLB.GermanyZLAB N.Mexico Index Membership
NASDAQ Golden Dragon China Index IPO Date
2017-09-20Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.85 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | -1.46 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.1 | |||||
Beneish M-Score | -3.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 23.2 | |||||
3-Year EBITDA Growth Rate | 31.7 | |||||
3-Year EPS without NRI Growth Rate | 23.8 | |||||
3-Year FCF Growth Rate | 28.5 | |||||
3-Year Book Growth Rate | -15.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 23.23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.84 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.91 | |||||
9-Day RSI | 60.57 | |||||
14-Day RSI | 52.86 | |||||
3-1 Month Momentum % | 1.75 | |||||
6-1 Month Momentum % | 0.16 | |||||
12-1 Month Momentum % | -49.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.4 | |||||
Quick Ratio | 2.19 | |||||
Cash Ratio | 1.68 | |||||
Days Inventory | 131.1 | |||||
Days Sales Outstanding | 66.13 | |||||
Days Payable | 221.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -3.81 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.91 | |||||
Operating Margin % | -52.19 | |||||
Net Margin % | -39.3 | |||||
EBITDA Margin % | -34.96 | |||||
FCF Margin % | -29.31 | |||||
OCF Margin % | -22.28 | |||||
ROE % | -23.81 | |||||
ROA % | -15.45 | |||||
ROIC % | -68.4 | |||||
3-Year ROIIC % | 65.49 | |||||
ROC (Joel Greenblatt) % | -90.19 | |||||
ROCE % | -22.05 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 234 | |||||
PS Ratio | 4.49 | |||||
PB Ratio | 3.11 | |||||
Price-to-Tangible-Book | 3.53 | |||||
EV-to-EBIT | -9.37 | |||||
EV-to-EBITDA | -10.29 | |||||
EV-to-Revenue | 3.6 | |||||
EV-to-Forward-Revenue | 3.42 | |||||
EV-to-FCF | -12.27 | |||||
Price-to-GF-Value | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 4.03 | |||||
| Price-to-Net-Cash | 9.03 | |||||
Earnings Yield (Greenblatt) % | -10.67 | |||||
FCF Yield % | -6.45 |
Zai Lab Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zai Lab Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 134 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 133 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:00 | In 43 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 42 days | ||
| General meeting for 2026 | 2026-06-17 08:00 | 17.73 (-0.78%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 21.01 (+0.14%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 21.01 (+0.14%) | ||
| Guidance call for 2026 | 2026-04-20 08:30 | 24.19 (+1.17%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:00 | 19.39 (+0.26%) | ||
| Annual report for 2025 | 2026-02-26 | 19.39 (+0.26%) |
Show
Entries
Guru Commentaries on NAS:ZLAB
No articles.
Press Release
Articles on Zai Lab Ltd
No articles.
Headlines
See More- 1
Jun 18, 2026
Novocure falls after late-stage trial setback for cancer treatment device
Seeking Alpha • 6:51am
Jun 09, 2026
Pfizer, Zai Lab win China nod for cervical cancer therapy Tivdak
Seeking Alpha • 6:30am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers